Study protocol of REpeat versus SIngle ShoT Antibiotic prophylaxis in major Abdominal Surgery (RESISTAAS I) : a prospective observational study of antibiotic prophylaxis practice for patients undergoing major abdominal surgery
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
INTRODUCTION: Surgical site infections (SSIs) are among the most common complications after abdominal surgery and develop in approximately 20% of patients. These patients suffer a 12% increase in mortality, underlying the need for strategies reducing SSI. Perioperative antibiotic prophylaxis is paramount for SSI prevention in major abdominal surgery. Yet, intraoperative redosing criteria are subjective and whether patients benefit from it remains unclear.
METHODS AND ANALYSIS: The REpeat versus SIngle ShoT Antibiotic prophylaxis in major Abdominal Surgery (RESISTAAS I) study is a single-centre, prospective, observational study investigating redosing of antibiotic prophylaxis in 300 patients undergoing major abdominal surgery. Adult patients scheduled for major abdominal surgery will be included. Current practice of redosing regarding number and time period will be recorded. Postoperative SSIs, nosocomial infections, clinically relevant infection-associated bacteria, postoperative antibiotic treatment, in addition to other clinical, pharmacological and economical outcomes will be evaluated. Differences between groups will be analysed with analysis of covariance.
ETHICS AND DISSEMINATION: RESISTAAS I will be conducted in accordance with the Declaration of Helsinki and internal, national and international standards of GCP. The Medical Ethics Review Board of Heidelberg University has approved the study prior to initiation (S-404/2021). The study has been registered on 7 February 2022 at German Clinical Trials Register, with identifier DRKS00027892. We plan to disseminate the results of the study in a peer-reviewed journal.
TRIAL REGISTRATION: German Clinical Trials Register (DRKS): DRKS00027892.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
BMJ open - 12(2022), 9 vom: 19. Sept., Seite e062088 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Murtha-Lemekhova, Anastasia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adult surgery |
|---|
| Anmerkungen: |
Date Completed 22.09.2022 Date Revised 11.10.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjopen-2022-062088 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346395887 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346395887 | ||
| 003 | DE-627 | ||
| 005 | 20231226205302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2022-062088 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346395887 | ||
| 035 | |a (NLM)36123092 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Murtha-Lemekhova, Anastasia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Study protocol of REpeat versus SIngle ShoT Antibiotic prophylaxis in major Abdominal Surgery (RESISTAAS I) |b a prospective observational study of antibiotic prophylaxis practice for patients undergoing major abdominal surgery |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.09.2022 | ||
| 500 | |a Date Revised 11.10.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a INTRODUCTION: Surgical site infections (SSIs) are among the most common complications after abdominal surgery and develop in approximately 20% of patients. These patients suffer a 12% increase in mortality, underlying the need for strategies reducing SSI. Perioperative antibiotic prophylaxis is paramount for SSI prevention in major abdominal surgery. Yet, intraoperative redosing criteria are subjective and whether patients benefit from it remains unclear | ||
| 520 | |a METHODS AND ANALYSIS: The REpeat versus SIngle ShoT Antibiotic prophylaxis in major Abdominal Surgery (RESISTAAS I) study is a single-centre, prospective, observational study investigating redosing of antibiotic prophylaxis in 300 patients undergoing major abdominal surgery. Adult patients scheduled for major abdominal surgery will be included. Current practice of redosing regarding number and time period will be recorded. Postoperative SSIs, nosocomial infections, clinically relevant infection-associated bacteria, postoperative antibiotic treatment, in addition to other clinical, pharmacological and economical outcomes will be evaluated. Differences between groups will be analysed with analysis of covariance | ||
| 520 | |a ETHICS AND DISSEMINATION: RESISTAAS I will be conducted in accordance with the Declaration of Helsinki and internal, national and international standards of GCP. The Medical Ethics Review Board of Heidelberg University has approved the study prior to initiation (S-404/2021). The study has been registered on 7 February 2022 at German Clinical Trials Register, with identifier DRKS00027892. We plan to disseminate the results of the study in a peer-reviewed journal | ||
| 520 | |a TRIAL REGISTRATION: German Clinical Trials Register (DRKS): DRKS00027892 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a adult surgery | |
| 650 | 4 | |a colorectal surgery | |
| 650 | 4 | |a gastrointestinal tumours | |
| 650 | 4 | |a infection control | |
| 650 | 4 | |a microbiology | |
| 650 | 4 | |a surgery | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Fuchs, Juri |e verfasserin |4 aut | |
| 700 | 1 | |a Teroerde, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Rau, Heike |e verfasserin |4 aut | |
| 700 | 1 | |a Frey, Otto R |e verfasserin |4 aut | |
| 700 | 1 | |a Hornuss, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Billeter, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Klotz, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Chiriac, Ute |e verfasserin |4 aut | |
| 700 | 1 | |a Larmann, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Weigand, Markus A |e verfasserin |4 aut | |
| 700 | 1 | |a Probst, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffmann, Katrin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2012 |g 12(2022), 9 vom: 19. Sept., Seite e062088 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:9 |g day:19 |g month:09 |g pages:e062088 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2022-062088 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 9 |b 19 |c 09 |h e062088 | ||